Status:

COMPLETED

Effects of Dehydration on Neuromuscular Performance and Sympathetic Control of Cardiovascular Function

Lead Sponsor:

United States Army Research Institute of Environmental Medicine

Conditions:

Dehydration Hypertonic

Isotonic Dehydration

Eligibility:

All Genders

18-45 years

Phase:

NA

Brief Summary

The mechanism(s) by which dehydration (both intra- and extracellular) impairs performance are still poorly described. A loss of volume results in increased occurrence of orthostatic intolerance, inclu...

Detailed Description

Study Objectives and Hypotheses Primary Objective The primary objectives of this study are to understand the in vivo effects of dehydration on: 1. Sympathetic neural control of cardiovascular funct...

Eligibility Criteria

Inclusion

  • Male or female, age 18-45
  • In good health as determined by OMSO General Medical Clearance
  • Passed his/her most recent Army Physical Fitness Test (APFT) (military volunteers only) or exercise at least 2 times per week (civilian volunteers)
  • Ability to comprehend and willingness to sign informed consent

Exclusion

  • Females who are pregnant or planning to become pregnant during the study
  • Taking prescription or over the counter medication, other than a contraceptive (unless approved by OMSO and PI)
  • Physical problems/injuries associated with walking or cycling
  • Allergy to sulfa drugs (Lasix™ or sulfonamide antibiotics such as Septra™)
  • Allergy to skin adhesive
  • Hemoglobinopathy (sickle cell trait)
  • Heart, lung, kidney, muscle, or nerve disorder(s)
  • History of heat or orthostatic intolerance
  • Diagnosed and/or treated for fluid/electrolyte imbalance within the last 30 days
  • Presence of metal implants/electronic medical devices in lower extremities
  • Current or previous (within the past 5 years) diagnosis of any autonomic disorder, including idiopathic orthostatic intolerance, orthostatic hypotension, postural tachycardia syndrome (POTS), or neurocardiogenic syncope (MSNA group only)
  • Tobacco/nicotine use (MSNA group only)
  • Significant muscle, joint, or bone injury affecting the legs within the last 6 months (CAC group only)
  • Difficulty swallowing large pills
  • History of obstructive disease of the gastrointestinal tract including (but not limited to) diverticulosis, diverticulitis and inflammatory bowel disease, peptic ulcer disease, Crohn's disease, ulcerative colitis; or previous gastrointestinal surgery.

Key Trial Info

Start Date :

October 31 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2017

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT03263975

Start Date

October 31 2014

End Date

December 1 2017

Last Update

April 22 2020

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.